Our nanotherapeutics-peptide micelles revolutionizes highly safe drug and gene delivery by targeting the disease sites and minimizing off-target side effect. Our nanotherapeutics will enhance therapeutic outcomes of existing medications, thereby extending patient lifespans.
PAMs can be designed to target the cystic tissues in the kidneys specifically, reducing the drug dose needed and minimizing side effects.
Deliver therapeutic agents directly to the vascular lesions, potentially reducing plaque formation and inflammation.
The versatility of PAM design allows for the development of personalized therapies, tailoring the peptide sequence and payload to individual patient needs.
PAMs has shown to be safe in multiple mice models and pigs.
